CytRx Corporation Receives Recommendation from Data Safety Monitoring Committee to Complete Global Phase 2b Clinical Trial With Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer

Published: Jan 31, 2013

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that the Data Safety Monitoring Committee overseeing the Company’s global Phase 2b clinical trial with tamibarotene in combination with chemotherapeutical agents as a first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) has recommended conducting the clinical trial through completion. Enrollment of at least 140 evaluable patients is expected in the first quarter of 2013.

Back to news